RGC
VRTX icon

Roberts, Glore & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Roberts, Glore & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Sell
3,197
-209
-6% -$92.6K 0.39% 60
2026
Q1 		$1.52M Sell
3,406
-284
-8% -$132K 0.42% 59
2025
Q4 		$1.67M Sell
3,690
-25
-0.7% -$10.8K 0.45% 54
2025
Q3 		$1.45M Buy
3,715
+93
+3% +$38.9K 0.4% 63
2025
Q2 		$1.61M Sell
3,622
-121
-3% -$55.8K 0.47% 56
2025
Q1 		$1.81M Sell
3,743
-345
-8% -$161K 0.55% 48
2024
Q4 		$1.65M Sell
4,088
-67
-2% -$31.1K 0.49% 54
2024
Q3 		$1.93M Sell
4,155
-187
-4% -$89.8K 0.56% 44
2024
Q2 		$2.04M Sell
4,342
-243
-5% -$105K 0.61% 42
2024
Q1 		$1.92M Sell
4,585
-272
-6% -$115K 0.57% 48
2023
Q4 		$1.98M Sell
4,857
-281
-5% -$104K 0.62% 45
2023
Q3 		$1.79M Sell
5,138
-14
-0.3% -$4.9K 0.59% 44
2023
Q2 		$1.81M Sell
5,152
-33
-0.6% -$11.1K 0.58% 45
2023
Q1 		$1.63M Sell
5,185
-29
-0.6% -$8.7K 0.55% 50
2022
Q4 		$1.51M Sell
5,214
-332
-6% -$101K 0.52% 53
2022
Q3 		$1.61M Sell
5,546
-105
-2% -$30.2K 0.57% 50
2022
Q2 		$1.59M Sell
5,651
-390
-6% -$104K 0.53% 50
2022
Q1 		$1.58M Hold
6,041
– – 0.45% 55
2021
Q4 		$1.33M Buy
6,041
+386
+7% +$75.1K 0.35% 64
2021
Q3 		$1.03M Buy
+5,655
New +$1.1M 0.31% 78

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Roberts, Glore & Co's VRTX Position: Q2 2026 in Review

Roberts, Glore & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 6.1% in Q2 2026, selling an estimated $92.6K and leaving 3,197 shares worth $1.59M. The position accounts for 0.39% of the portfolio, ranked #60.

Roberts, Glore & Co first reported a position in VRTX in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.04M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Roberts, Glore & Co held 3,197 shares of Vertex Pharmaceuticals worth $1.59M as of Q2 2026.
  • Roberts, Glore & Co sold 209 Vertex Pharmaceuticals shares in Q2 2026, an estimated $92.6K.
  • Vertex Pharmaceuticals made up 0.39% of Roberts, Glore & Co's portfolio in Q2 2026, its #60 holding.
  • Roberts, Glore & Co first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Roberts, Glore & Co's Vertex Pharmaceuticals position peaked at $2.04M in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Roberts, Glore & Co's 13F filing for Q2 2026, filed 11 Aug 2026.